ABSTRACT
Purpose@#Gamma-glutamyl transferase (GGT) has been reported as being involved in tumor progression. Previous studies documented a potential relationship between serum GGT level and survival outcome in several types of human malignancies. However, the association between serum GGT levels and response to neoadjuvant chemotherapy (NAC) has not yet been reported. The present study aimed to evaluate the association between pre-therapeutic serum GGT level and the efficacy, long-term survival, and adverse reactions of NAC and to investigate its role in predicting NAC sensitivity in patients with breast cancer. @*Methods@#A total of 129 patients were recruited and stratified into 2 groups according to serum GGT level (< 29 U/L and ≥ 29 U/L). The association between pre-therapeutic serum GGT levels and clinicopathological parameters was examined. The correlation between pre-therapeutic serum GGT levels and pathological complete response (pCR) was analyzed using univariate and multivariate logistic regression. Survival analyses of relapse-free survival (RFS) and disease-free survival (DFS) were performed. Pearson's χ 2 test and multivariate logistic regression model were used to analyze the correlation between pre-therapeutic serum GGT levels and adverse reactions. @*Results@#Pre-therapeutic serum GGT levels were associated with pCR among breast cancer patients treated with NAC. Multivariate analysis showed that low-level GGT significantly increased pCR rate. Patients in the high-level GGT group had poorer survival than those in the low-level GGT group. Subgroup analysis demonstrated that serum GGT level was potentially related to RFS and DFS in the hormone receptor-positive group. Low levels of GGT are significantly associated with a higher incidence of neutropenia. @*Conclusion@#Pre-therapeutic serum GGT level is an independent and novel biomarker for predicting the efficiency, prognosis, and adverse reactions to NAC in breast cancer patients.Patients with low pre-therapeutic serum GGT levels are more likely to have higher pCR rates, better RFS and DFS, and higher hematologic toxicity.
ABSTRACT
Purpose@#Gamma-glutamyl transferase (GGT) has been reported as being involved in tumor progression. Previous studies documented a potential relationship between serum GGT level and survival outcome in several types of human malignancies. However, the association between serum GGT levels and response to neoadjuvant chemotherapy (NAC) has not yet been reported. The present study aimed to evaluate the association between pre-therapeutic serum GGT level and the efficacy, long-term survival, and adverse reactions of NAC and to investigate its role in predicting NAC sensitivity in patients with breast cancer. @*Methods@#A total of 129 patients were recruited and stratified into 2 groups according to serum GGT level (< 29 U/L and ≥ 29 U/L). The association between pre-therapeutic serum GGT levels and clinicopathological parameters was examined. The correlation between pre-therapeutic serum GGT levels and pathological complete response (pCR) was analyzed using univariate and multivariate logistic regression. Survival analyses of relapse-free survival (RFS) and disease-free survival (DFS) were performed. Pearson's χ 2 test and multivariate logistic regression model were used to analyze the correlation between pre-therapeutic serum GGT levels and adverse reactions. @*Results@#Pre-therapeutic serum GGT levels were associated with pCR among breast cancer patients treated with NAC. Multivariate analysis showed that low-level GGT significantly increased pCR rate. Patients in the high-level GGT group had poorer survival than those in the low-level GGT group. Subgroup analysis demonstrated that serum GGT level was potentially related to RFS and DFS in the hormone receptor-positive group. Low levels of GGT are significantly associated with a higher incidence of neutropenia. @*Conclusion@#Pre-therapeutic serum GGT level is an independent and novel biomarker for predicting the efficiency, prognosis, and adverse reactions to NAC in breast cancer patients.Patients with low pre-therapeutic serum GGT levels are more likely to have higher pCR rates, better RFS and DFS, and higher hematologic toxicity.
ABSTRACT
To explore predictive value of fragmented QRS wave (fQRS) for prognosis in patients with a‐cute no ST elevation myocardial infarction (NSTEMI).Methods : According to ECG measure result , 120 NSTEMI patients treated in our hospital from Jan 2015 to Feb 2017 were divided into fQRS group (n＝73) and no fQRS group (n＝47).Both groups received same treatment .General information and incidence of MACE during one‐year fol‐low‐up were compared between two groups .Results : There were no significant difference in heart rate ,percentage of dyslipidemia ,hypertension and diabetes mellitus between two groups ( P＞ 0. 05 all).Compared with no fQRS group ,there were significant reduction in left ventricular ejection fraction [(63. 81 ± 5.67)% vs.(52. 18 ± 5. 81)%, P＝0. 001] , and significant rise in percentage of previous myocardial infarction (21.28% vs.39. 73%, P＝0.035) and more than three coronary stenosis greater than or equal to 50%(36.17% vs.54.79%, P＝ 0.046) in fQRS group .Compared with no fQRS group ,incidence of MACE of fQRS group was higher (25. 53% vs.45.21%, P＝0.030).Conclusion :Cardiac function of NSTEMI patients with fQRS is significantly poorer than that of patients without fQRS ,so patients with fQRS predicts their state of an illness is serious and prognosis is poor .